Quartel Adrian W
Transaction: 07/27/2026
OTHER
Change
0
Price
Not reported
Filing
07/29/2026
Type
OTHER
Spruce Biosciences, Inc.
SPRB • Biotechnology
$57.93
▲ +0.22 (+0.38%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$140.30M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.02Healthy liquidity · 5.17Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:23 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$57.93
Change0.38%
Shares Out2.43M
Market Cap$140.30M
Enterprise Value$46.75M
52W Range7.00 - 240.00
Beta3.34
P/E-3.99
P/B1.68
P/FCF-3.28
EV/EBITDA-0.92
EV/FCF-1.09
Price$57.93
Change0.38%
Shares Out2.43M
Market Cap$140.30M
Enterprise Value$46.75M
52W Range7.00 - 240.00
Beta3.34
P/E-3.99
P/B1.68
P/FCF-3.28
EV/EBITDA-0.92
EV/FCF-1.09
Earnings Yield-25.04%
FCF Yield-30.48%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.02
Current Ratio5.17
Quick Ratio5.17
Target$131.33
Target Upside126.70%
Target Median$140.00
Target Range104.00 - 150.00
Volume50.69K
Avg Volume70.75K
EPS Surprise-1.62
Investment DNA
How strong this company looks for long-term investors
41
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
90/100
Why this score▼
Manageable debt level · 0.02Healthy liquidity · 5.17Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 11 analyst votes · 2026-09-04
82/100
Bullish
Bullish
7
Hold
4
Bearish
0
Price Target
2026-08-14
Low
$123.00
Mean
$137.67
Median
$140.00
High
$150.00
Insider Transactions
Recent executive and insider activity
Quartel Adrian W
Transaction: 07/27/2026
BUY
Change
+13,000
Price
Not reported
Filing
07/29/2026
Type
BUY
Szwarcberg Javier B.
Transaction: 06/30/2026
BUY
Change
+266
Price
$4.53
Filing
07/09/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Quartel Adrian W | OTHER | 0 | Not reported | 07/27/2026 | 07/29/2026 |
| Quartel Adrian W | BUY | +13,000 | Not reported | 07/27/2026 | 07/29/2026 |
| Szwarcberg Javier B. | BUY | +266 | $4.53 | 06/30/2026 | 07/09/2026 |
| Walbert Keli | BUY | +1,700 | $52.70 | 05/21/2026 | 05/26/2026 |
| Barretto-Ko Percival | BUY | +1,700 | $52.70 | 05/21/2026 | 05/26/2026 |
| GREY MICHAEL G | BUY | +1,700 | $52.70 | 05/21/2026 | 05/26/2026 |
| SIMPSON CAMILLA V | BUY | +1,700 | $52.70 | 05/21/2026 | 05/26/2026 |
| SPIEGELMAN DANIEL K | BUY | +1,700 | $52.70 | 05/21/2026 | 05/26/2026 |
| Hooks Corwin Dale | OTHER | 0 | Not reported | 03/09/2026 | 03/09/2026 |
| Hooks Corwin Dale | BUY | +11,000 | Not reported | 03/09/2026 | 03/09/2026 |
| Ways Douglas Kirk | SELL | -400 | $169.50 | 12/11/2025 | 01/21/2026 |
| Ways Douglas Kirk | BUY | +1,250 | Not reported | 12/11/2025 | 01/21/2026 |
| Ways Douglas Kirk | SELL | -1,250 | Not reported | 12/11/2025 | 01/21/2026 |
| Szwarcberg Javier B. | BUY | +4,690 | $4.53 | 12/31/2025 | 01/05/2026 |
| Szwarcberg Javier B. | SELL | -1,480 | Not reported | 12/15/2025 | 12/17/2025 |
| Szwarcberg Javier B. | SELL | -752 | $80.67 | 12/15/2025 | 12/17/2025 |
| Gharib Samir M. | SELL | -496 | Not reported | 12/15/2025 | 12/17/2025 |
| Gharib Samir M. | SELL | -178 | $80.67 | 12/15/2025 | 12/17/2025 |
| Szwarcberg Javier B. | BUY | +1,666 | $104.13 | 12/11/2025 | 12/17/2025 |
| Walbert Keli | OTHER | 0 | Not reported | 12/11/2025 | 12/15/2025 |